Literature DB >> 25421919

The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population.

Birgit G Skov1, Estrid Høgdall, Paul Clementsen, Mark Krasnik, Klaus Richter Larsen, Jens Benn Sørensen, Torsten Skov, Anders Mellemgaard.   

Abstract

EGFR mutation frequencies in unselected Caucasian populations are unknown. This study assesses the prevalence of EGFR mutations in an unselected population-based cohort, and the correlation between mutation and gender, age, ethnicity, smoking habits, and pathological data. NSCLC patients diagnosed in a well-defined Danish population were included. The type of the diagnostic material, and data on smoking were registered. The mutation analyses were investigated by Therascreen EGFR RGQ-PCR Kit or Sanger sequencing. A total of 658 men and 598 women were included. 6.2% were never smokers, 38.9% were ex-smokers, and 54.9% were current smokers. One thousand one hundred and sixty-one (92.4%) patients had sufficient material for mutation analysis. Cytological material was used for 38% of the mutation analyses. 5.4% had mutation in the EGFR gene (4.3% men/6.7% women). 87% were activating mutations. 8.0% of adenocarcinomas, and 1.9% of squamous cell carcinomas were mutated. 29.4%, 4.4% and 2.9% of never, ex- and current smokers were mutated (p < 0.001). No difference in mutation rate was observed between patients with cytology only, histology only or both cytology and histology available. 5.4% of the patients had EGFR mutation. Adenocarcinomas were mutated more often (8.0%) than squamous cell carcinomas (1.9%). Mutations were found in never smokers as well as in former and current smokers. No difference in gender and age regarding mutation status was observed. EGFR mutations analysis was possible in almost all patients with no difference between cytology and histology specimens.
© 2014 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  EGFR mutations; NSCLC; cytology; population based

Mesh:

Substances:

Year:  2014        PMID: 25421919     DOI: 10.1111/apm.12328

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  21 in total

1.  Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.

Authors:  C Kuempers; L I S van der Linde; M Reischl; W Vogel; F Stellmacher; M Reck; D Heigener; K F Rabe; J Kirfel; S Perner; L Welker
Journal:  Virchows Arch       Date:  2019-08-07       Impact factor: 4.064

2.  Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).

Authors:  M Faehling; J Achenbach; P Staib; U Steffen; H W Tessen; V E Gaillard; W Brugger
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-23       Impact factor: 4.553

3.  Discrepancies between ALK protein disruption and occurrence of ALK gene rearrangement in Polish NSCLC patients.

Authors:  Anna Grenda; Bożena Jarosz; Paweł Krawczyk; Tomasz Kucharczyk; Kamila Wojas-Krawczyk; Katarzyna Reszka; Kinga Krukowska; Marcin Nicoś; Juliusz Pankowski; Maciej Bryl; Rodryg Ramlau; Barbara Kuźnar-Kamińska; Tomasz Grodzki; Aleksandra Szczęsna; Krystyna Siemiątkowska; Justyna Szumiło; Halina Batura-Gabryel; Michał Palonka; Janusz Milanowski
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 4.  Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors.

Authors:  Weijie Gu; Yao Zhu; Dingwei Ye
Journal:  Transl Androl Urol       Date:  2017-10

Review 5.  Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).

Authors:  Kaidi Li; Maojun Yang; Naixin Liang; Shanqing Li
Journal:  Oncol Rep       Date:  2017-01-30       Impact factor: 3.906

6.  Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: A study of 600 cases from a single center.

Authors:  Malahat Musayeva; Serpil Dizbay Sak; Hilal Özakıncı; Şenay Boyacıgil; Öznur Coşkun
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-01-23       Impact factor: 0.332

7.  Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.

Authors:  Bregje M Koomen; Jose van der Starre-Gaal; Judith M Vonk; Jan H von der Thüsen; Jacqueline J C van der Meij; Kim Monkhorst; Stefan M Willems; Wim Timens; Nils A 't Hart
Journal:  Cancer Cytopathol       Date:  2020-10-27       Impact factor: 5.284

8.  Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey.

Authors:  Sang Hwa Lee; Wan Seop Kim; Yoo Duk Choi; Jeong Wook Seo; Joung Ho Han; Mi Jin Kim; Lucia Kim; Geon Kook Lee; Chang Hun Lee; Mee Hye Oh; Gou Young Kim; Sun Hee Sung; Kyo Young Lee; Sun Hee Chang; Mee Sook Rho; Han Kyeom Kim; Soon Hee Jung; Se Jin Jang
Journal:  J Pathol Transl Med       Date:  2015-10-13

9.  Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey.

Authors:  Sebnem Ozemri Sag; Ozlem Gorukmez; Mehmet Ture; Orhan Gorukmez; Adem Deligonul; Serdar Sahinturk; Ali Topak; Tuna Gulten; Ender Kurt; Tahsin Yakut
Journal:  Springerplus       Date:  2016-04-19

Review 10.  Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.

Authors:  Pranshu Bansal; Diaa Osman; Gregory N Gan; George R Simon; Yanis Boumber
Journal:  Front Oncol       Date:  2016-05-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.